Clinical Trials
Pegylated Interferon Alfa-2b
Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia ClinicalTrials.gov ID NCT05395507 Sponsor Institute of Hematology & Blood Diseases Hospital, China
Year: 2025
Clinical Trials
Recombinant Interleukin-15
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers ClinicalTrials.gov ID NCT03388632 Sponsor National Cancer Institute (NCI) Information provided by National Institutes of Health Clinical Center (CC) (National Cancer Institute (NCI)) (Responsible Party)
Clinical Trials
Role of IL-5R Signaling
Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP (RECAP-5) ClinicalTrials.gov ID NCT05672030 Sponsor Brigham and Women’s Hospital Information provided by Tanya Laidlaw, MD, Brigham and Women’s Hospital (Responsible Party)
Member Highlights
Member Highlight: Meet Yanick Crow, M.D., Ph.D.
The following interview was conducted by Signals+ Editor Maialen Sebastian-delaCruz, Ph.D. Connect with her on LinkedIn. The best life/career advice I have ever received was, “The harder you work, the luckier you get.” In the Crow Lab, we are interested in human monogenic diseases associated with chronically enhanced production of type I interferons [READ MORE]
Members in the News
Past-Presidents Dr Christopher A Hunter and Dr Warren J Leonard named AAI Distinguished Fellows
Congratulations Chris Hunter and Warren Leonard! Dr Christopher A Hunter and Dr Warren J Leonard were selected as Distinguished Fellows of the American Association of Immunologists (AAI) in this year’s class. Dr Hunter and Dr Leonard are Past-Presidents of International Cytokine and Interferon Society (ICIS) and of the International Cytokine [READ MORE]
Special Article of Interest
“Regulation of human interferon signaling by transposon exonization” published in Cell
The following interview was conducted by Signals+ Editor Maialen Sebastian-delaCruz, Ph.D. Connect with her on LinkedIn. A recent study by Pasquesi et al from the Chuong lab published in Cell, “Regulation of human interferon signaling by transposon exonization” showed that transposable element exonization can yield functional protein isoforms as seen for [READ MORE]
Member Highlights
Member Highlight: Meet Elias Said
The following interview was conducted by Signals+ Editor Maialen Sebastian-delaCruz, Ph.D. Connect with her on LinkedIn. I am a researcher in the Immunology field, specifically innate immunity and cytokines. Also, an Associate Editor for scientific journals. My research has led to significant achievements, such as identifying the role of PD-1 in [READ MORE]
Clinical Trials
Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia
ClinicalTrials.gov ID NCT05600920 Sponsor National Institute of Allergy and Infectious Diseases (NIAID) Information provided by National Institutes of Health Clinical Center (CC) (National Institute of Allergy and Infectious Diseases (NIAID)) Study Overview Brief Summary Background: Idiopathic CD4 lymphopenia (ICL) is a syndrome characterized by low levels of certain immune cells [READ MORE]
Clinical Trials
Serum IL 26 as a Marker of Disease Activity in SLE
ClinicalTrials.gov ID NCT05161988 Sponsor: Assiut University Information provided by Fatma alzahraa Mustafa Abdelbary Thabet, Assiut University (Responsible Party) Study Overview Brief Summary Assessment of serum Interleukin 26 level in SLE patients and compare it with healthy controls. Association of serum interleukin 26 with SLE activity and severity. Detailed Description Systemic [READ MORE]
Clinical Trials
Cancer Ratio,Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}for Differentiation Between Malignant and Non Malignant Pleural Effusion
ClinicalTrials.gov ID NCT05693727 Sponsor: Assiut University Information provided by Mona Adel, Assiut University (Responsible Party) Study Overview Brief Summary To evaluate the ability of cancer ratio and pleural fluid markers to discriminate between malignant and non malignant effusion Detailed Description Pleural effusion is a common clinical entity affecting approximately 1.5 [READ MORE]